tiprankstipranks
Corcept Therapeutics Inc. (CH:HTD)
:HTD
Switzerland Market
HTD
Corcept Therapeutics
RESEARCH TOOLSreports

Corcept Therapeutics (HTD) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HTD Analyst Ratings

Moderate Buy
4Ratings
Moderate Buy
3 Buy
0 Hold
1 Sell
Based on 4 analysts giving stock ratings to
Corcept
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HTD Stock 12 Month Forecast

Average Price Target

―
Based on 4 Wall Street analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is CHF110.04 with a high forecast of CHF134.25 and a low forecast of CHF40.68. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF134.25Average Price TargetCHF110.04Lowest Price TargetCHF40.68
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on CH:HTD
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF130.99
Buy
―
Reiterated
08/13/26
Canaccord Genuity Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
Piper Sandler Analyst forecast on CH:HTD
David Amsellem
Piper Sandler
Piper Sandler
CHF71.6→CHF134.25
Buy
―
Reiterated
07/30/26
Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
H.C. Wainwright Analyst forecast on CH:HTD
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
CHF77.29→CHF134.25
Buy
―
Reiterated
07/30/26
Corcept Therapeutics price target raised to $165 from $95 at H.C. WainwrightCorcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright
Wolfe Research Analyst forecast on CH:HTD
Kalpit Patel
Wolfe Research
Wolfe Research
CHF40.68
Sell
―
Reiterated
07/29/26
Corcept: Strong Lifyorli Launch But Legal and Regulatory Risks Keep Sell Rating and $50 Price Target Unchanged
UBS Analyst forecast on CH:HTD
Ashwani Verma
UBS
UBS
CHF58.58
Buy
―
Upgraded
05/13/26
Corcept Therapeutics upgraded to Buy from Neutral at UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS
Truist Financial Analyst forecast on CH:HTD
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/02/26
Wall Street Analysts Are Bullish on Top NA Picks
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on CH:HTD
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF130.99
Buy
―
Reiterated
08/13/26
Canaccord Genuity Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
Piper Sandler Analyst forecast on CH:HTD
David Amsellem
Piper Sandler
Piper Sandler
CHF71.6→CHF134.25
Buy
―
Reiterated
07/30/26
Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
H.C. Wainwright Analyst forecast on CH:HTD
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
CHF77.29→CHF134.25
Buy
―
Reiterated
07/30/26
Corcept Therapeutics price target raised to $165 from $95 at H.C. WainwrightCorcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright
Wolfe Research Analyst forecast on CH:HTD
Kalpit Patel
Wolfe Research
Wolfe Research
CHF40.68
Sell
―
Reiterated
07/29/26
Corcept: Strong Lifyorli Launch But Legal and Regulatory Risks Keep Sell Rating and $50 Price Target Unchanged
UBS Analyst forecast on CH:HTD
Ashwani Verma
UBS
UBS
CHF58.58
Buy
―
Upgraded
05/13/26
Corcept Therapeutics upgraded to Buy from Neutral at UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS
Truist Financial Analyst forecast on CH:HTD
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/02/26
Wall Street Analysts Are Bullish on Top NA Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corcept Therapeutics

3 Months
Swayampakula RamakanthH.C. Wainwright
Success Rate
14/19 ratings generated profit
74%
Average Return
+23.29%
Copying Swayampakula Ramakanth's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +23.29% per trade.
1 Year
David AmsellemPiper Sandler
Success Rate
23/27 ratings generated profit
85%
Average Return
+68.74%
Copying David Amsellem's trades and holding each position for 1 Year would result in 85.19% of your transactions generating a profit, with an average return of +68.74% per trade.
2 Years
David AmsellemPiper Sandler
Success Rate
27/27 ratings generated profit
100%
Average Return
+115.90%
Copying David Amsellem's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +115.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HTD Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
14
11
5
3
0
Buy
2
5
5
10
8
Hold
1
1
0
0
0
Sell
0
0
0
2
2
Strong Sell
0
0
0
0
0
total
17
17
10
15
10
In the current month, HTD has received 8 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. HTD average Analyst price target in the past 3 months is 110.04.
Each month's total comprises the sum of three months' worth of ratings.

HTD Financial Forecast

HTD Earnings Forecast

Next quarter’s earnings estimate for HTD is CHF0.64 with a range of CHF0.50 to CHF0.84. The previous quarter’s EPS was CHF0.29. HTD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.
Next quarter’s earnings estimate for HTD is CHF0.64 with a range of CHF0.50 to CHF0.84. The previous quarter’s EPS was CHF0.29. HTD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.

HTD Sales Forecast

Next quarter’s sales forecast for HTD is CHF261.07M with a range of CHF222.93M to CHF284.77M. The previous quarter’s sales results were CHF208.41M. HTD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.
Next quarter’s sales forecast for HTD is CHF261.07M with a range of CHF222.93M to CHF284.77M. The previous quarter’s sales results were CHF208.41M. HTD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.

HTD Stock Forecast FAQ

What is CH:HTD’s average 12-month price target, according to analysts?
Based on analyst ratings, Corcept Therapeutics Inc.’s 12-month average price target is 110.04.
    What is CH:HTD’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:HTD, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Corcept Therapeutics Inc. a Buy, Sell or Hold?
        Corcept Therapeutics Inc. has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 0 hold ratings and 1 sell ratings.
          What is Corcept Therapeutics Inc.’s share price target?
          The average share price target for Corcept Therapeutics Inc. is 110.04. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF134.25 ,and the lowest forecast is CHF40.68. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Corcept Therapeutics Inc.?
            Corcept Therapeutics Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
              How can I buy shares of Corcept Therapeutics Inc.?
              To buy shares of CH:HTD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.